It was also suggested that TP53 mutation is a terminal genetic event in the development of MDS since mutations were detected in four out of eight cases of advanced MDS subtypes (refractory anemia with excessive blast, and AML from MDS), but not in 16 cases of the less advanced subtypes [528]. This evidence concerns the gene TP53 and acute myeloid leukemia.